JNJ to Report Q3 Earnings Amid Optimism Over New Therapies

Johnson & Johnson is set to release its Q3 earnings on October 13. The company's quarterly earnings are expected to be $2.48 per share, a decline from last year's $2.80 per share.

The consensus estimate for JNJ's quarterly revenue is $25.31 billion, up from $23.99 billion reported in the previous year.

Recent clinical evaluations have shown positive findings for Johnson & Johnson's therapies, Tremfya and Carvykti, in treating psoriatic arthritis and multiple myeloma.

Analysts have revised their price targets for JNJ stock, with JP Morgan's Chris Scott increasing his target from $270 to $285 on September 29. HSBC's Rajesh Kumar raised his target from $290 to $320 on September 10, while UBS' Michael Yee boosted his target from $280 to $320 on September 2.

Guggenheim's Vamil Divan maintained a Buy rating and increased the price target from $270 to $287 on August 6. Wells Fargo's Larry Beigelsen maintained an Overweight rating and raised his target from $272 to $282 on August 3.